PROCESS SOLUTIONS
Process Solutions experts collaborate with the world's leading drug developers to help bring life-saving and life-enhancing drug therapies to patients, faster. The expertise, products and services we offer help drug manufacturers develop, make, purify, formulate and assure their drugs, as well as ensure that they meet regulatory safety standards.
We are transforming the path from treatments to cures. Alongside pharmaceutical manufacturers, we advance important molecules across our five franchises: bioprocessing, actives & formulation, end-to-end, gene editing and novel modalities, and testing services.
We provide the industry’s most comprehensive portfolio of high-quality products, services and testing for biopharmaceutical manufacturing. Our products and services are critical for diseases such as breast cancer, lymphoma, diabetes, multiple sclerosis, migraines, Crohn's Disease, pediatric brain cancer, and COVID-19. For decades, we have collaborated with our customers to shape how drug production is done today and will continue to shape the possibilities of tomorrow.
The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.
Apply below for our Associate Scientist Positions and have a virtual interview with our hiring managers for a day-of hiring decision!
Date: October 20, 2021!
Apply below for our Associate Scientist Positions and have a virtual interview with our hiring managers for a day-of hiring decision!
Date: October 20, 2021!
Andrew Bulpin Executive VP, Head of Process Solutions
Andrew Bulpin is Head of the Process Solutions Business Unit. In this role, he oversees R&D, Product Management and Marketing, the Services organization, as well as the Process Solutions Commercial teams. Bulpin has held several roles since joining Millipore in 2006 as VP for the Upstream Processing business and later assumed leadership of the Services and Solutions business.
Andrew holds a Ph.D. in Organic Chemistry from the Université de Caen, France, a MBA from the University of Strathclyde, Scotland, and a Bachelor degree from the University of Sussex, England.
What we do
Process Solutions helps our customers develop, make, purify, formulate and assure the quality of life-enhancing and life-saving drugs across our five franchises: bioprocessing, actives & formulations, end-to-end, gene editing & novel modalities, and testing services
Our Portfolio
Process Solutions portfolio products and services are sold under three major brands: Millipore®, SAFC® or BioReliance®.
-
Andrew Bulpin Executive VP, Head of Process Solutions
Andrew Bulpin is Head of the Process Solutions Business Unit. In this role, he oversees R&D, Product Management and Marketing, the Services organization, as well as the Process Solutions Commercial teams. Bulpin has held several roles since joining Millipore in 2006 as VP for the Upstream Processing business and later assumed leadership of the Services and Solutions business.
Andrew holds a Ph.D. in Organic Chemistry from the Université de Caen, France, a MBA from the University of Strathclyde, Scotland, and a Bachelor degree from the University of Sussex, England.
-
Our Portfolio
Process Solutions portfolio products and services are sold under three major brands: Millipore®, SAFC® or BioReliance®.
-
What we do
Process Solutions helps our customers develop, make, purify, formulate and assure the quality of life-enhancing and life-saving drugs across our five franchises: bioprocessing, actives & formulations, end-to-end, gene editing & novel modalities, and testing services
Learn more about us:
- MilliporeSigma’s Latest Technologies Earn Industry Recognition for Accelerating Bioprocessing 4.0
- MilliporeSigma and Transcenta Collaborate to Advance Continuous Biomanufacturing, Make the ‘Facility of the Future’ a Reality
- MilliporeSigma Awards Grant to Combined Therapeutics for its Nucleic Acid Platform That, with Virotherapy, Targets Liver Cancer
- MilliporeSigma’s New VirusExpress™ Platform Speeds Development of Cell and Gene Therapies
- MilliporeSigma Licenses CRISPR Genome-Editing Technology to PanCELLa and Takara Bio USA
- Merck KGaA, Darmstadt, Germany, Announces € 59 Million Antibody-Drug Conjugate Manufacturing Expansion
- MilliporeSigma Announces VAR2 Pharmaceuticals as Winner of its Advance Biotech Grant
- MilliporeSigma and 10x Genomics Launch Powerful New Option for CRISPR Research
- Merck KGaA, Darmstadt, Germany and Baylor College of Medicine Announce Collaboration to Advance a Vaccine Manufacturing Platform to Fight Covid-19
- Merck KGaA, Darmstadt, Germany Announces Boost to Commercial Viral Vector and Gene Therapy Manufacturing Capacity
Screen readers cannot read the following searchable map.
Follow this link to reach our Job Search page to search for available jobs in a more accessible format.
BE CURIOUS AND STAY CONNECTED
Enter your email and tell us a bit about yourself, and we will keep you updated about latest company news and information about career opportunities that match your interests.
Already signed-up?